WO2002041875A3 - Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen - Google Patents

Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen Download PDF

Info

Publication number
WO2002041875A3
WO2002041875A3 PCT/EP2001/012322 EP0112322W WO0241875A3 WO 2002041875 A3 WO2002041875 A3 WO 2002041875A3 EP 0112322 W EP0112322 W EP 0112322W WO 0241875 A3 WO0241875 A3 WO 0241875A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
readily soluble
soluble medicament
producing readily
producing
Prior art date
Application number
PCT/EP2001/012322
Other languages
English (en)
French (fr)
Other versions
WO2002041875A2 (de
Inventor
Kurt-Heinz Bauer
Norbert Otterbeck
Original Assignee
Falk Pharma Gmbh
Kurt-Heinz Bauer
Norbert Otterbeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Falk Pharma Gmbh, Kurt-Heinz Bauer, Norbert Otterbeck filed Critical Falk Pharma Gmbh
Priority to AU2002223645A priority Critical patent/AU2002223645A1/en
Publication of WO2002041875A2 publication Critical patent/WO2002041875A2/de
Publication of WO2002041875A3 publication Critical patent/WO2002041875A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft eine pharmazeutische Formulierung zur Verabreichung eines Wirkstoffs, insbesondere eines schwer löslichen und/oder schwer benetzbaren Wirkstoffs wie einem Corticosteroid oder 6-Thioguanin. Ein Verfahren zur Herstellung einer solchen Formulierung ist ebenfalls offenbart.
PCT/EP2001/012322 2000-11-27 2001-10-25 Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen WO2002041875A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002223645A AU2002223645A1 (en) 2000-11-27 2001-10-25 Method for producing readily soluble medicament formulations and corresponding formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10058772.0 2000-11-27
DE2000158772 DE10058772A1 (de) 2000-11-27 2000-11-27 Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen

Publications (2)

Publication Number Publication Date
WO2002041875A2 WO2002041875A2 (de) 2002-05-30
WO2002041875A3 true WO2002041875A3 (de) 2002-11-14

Family

ID=7664790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012322 WO2002041875A2 (de) 2000-11-27 2001-10-25 Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen

Country Status (3)

Country Link
AU (1) AU2002223645A1 (de)
DE (1) DE10058772A1 (de)
WO (1) WO2002041875A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005749A1 (en) * 2011-06-10 2013-01-03 The University Of Queensland Novel formulation and treatment methods
CA3038602C (en) 2015-09-29 2023-12-05 ProdrugXtend Pty Ltd Extended-release formulations comprising 6-thioguanine
DE102018133374A1 (de) * 2018-12-21 2020-06-25 Gelita Ag Kollagenhydrolysat zur Verwendung gegen Hautkrankheiten und Darmkrankheiten

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726615A (en) * 1980-07-23 1982-02-12 Grelan Pharmaceut Co Ltd Improving method for absorbability of slightly soluble drug
EP0344603A1 (de) * 1988-05-30 1989-12-06 Zeria Pharmaceutical Co., Ltd. Pharmazeutische Zusammensetzung die ein Dihydropyridinderivat enthält
EP0474098A1 (de) * 1990-08-30 1992-03-11 Senju Pharmaceutical Co., Ltd. Zusammensetzung zur kontrollierten Abgabe von Medikamenten
EP0521310A2 (de) * 1991-06-05 1993-01-07 FUJIREBIO Inc. 1,4-Dihydropyridin-Derivate enthaltende Tabletten des Typs Feststoffdispersion und Verfahren zu deren Herstellung
WO1994019411A1 (en) * 1993-02-19 1994-09-01 Danochemo A/S Process for the preparation of a water-dispersible carotenoid preparation in powder form
US5902606A (en) * 1992-07-03 1999-05-11 Alfatec-Pharma Gmbh Solid and liquid solutions of sparingly water-soluble medicinal substances
WO2000027363A1 (en) * 1998-11-12 2000-05-18 Elan Pharma International Ltd. Aerosols comprising nanoparticle drugs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726615A (en) * 1980-07-23 1982-02-12 Grelan Pharmaceut Co Ltd Improving method for absorbability of slightly soluble drug
EP0344603A1 (de) * 1988-05-30 1989-12-06 Zeria Pharmaceutical Co., Ltd. Pharmazeutische Zusammensetzung die ein Dihydropyridinderivat enthält
EP0474098A1 (de) * 1990-08-30 1992-03-11 Senju Pharmaceutical Co., Ltd. Zusammensetzung zur kontrollierten Abgabe von Medikamenten
EP0521310A2 (de) * 1991-06-05 1993-01-07 FUJIREBIO Inc. 1,4-Dihydropyridin-Derivate enthaltende Tabletten des Typs Feststoffdispersion und Verfahren zu deren Herstellung
US5902606A (en) * 1992-07-03 1999-05-11 Alfatec-Pharma Gmbh Solid and liquid solutions of sparingly water-soluble medicinal substances
WO1994019411A1 (en) * 1993-02-19 1994-09-01 Danochemo A/S Process for the preparation of a water-dispersible carotenoid preparation in powder form
WO2000027363A1 (en) * 1998-11-12 2000-05-18 Elan Pharma International Ltd. Aerosols comprising nanoparticle drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRELAN PHARMACEUTICAL CO., LTD., JAPAN: "Enhancement of solubility and bioavailability of drugs by incorporation o soluble proteins in formulations", XP002201835, retrieved from STN Database accession no. 96:205427 CA *
DATABASE WPI Section Ch Week 198212, Derwent World Patents Index; Class A03, AN 1982-22874E *

Also Published As

Publication number Publication date
WO2002041875A2 (de) 2002-05-30
DE10058772A1 (de) 2002-06-06
AU2002223645A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2004026231A3 (en) Formulation for lipophilic agents
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO1999053910A3 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
EP1589947B8 (de) Pharmazeutische formulierung enthaltend einen unlöslichen wirkstoff zur pulmonalen verabreichung
CA2386690A1 (en) Pharmaceutical tramadol salts
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
EP1040823A3 (de) Stabile Schaumzusammensetzungen
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2001041742A3 (en) Antiviral medication
EP2308479A3 (de) Verbindungen und Zusammensetzungen zur Wirkstofffreisetzung
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
WO2001085139A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
WO2003041656A3 (en) Soluble drug extended release system
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP